Articles from Ethyreal Bio, Inc.

Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
– ETHY-001 targets the causal pathogenic mechanism underlying both conditions –
By Ethyreal Bio, Inc. · Via GlobeNewswire · June 10, 2026